Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males.

Zhu J, Song M, Tan HY, Huang LH, Huang ZJ, Liu C, Fu ZM, Huang YY, Tan ZR, Chen XP, Yuan H, Yang GP.

Pak J Pharm Sci. 2013 May;26(3):577-84.

PMID:
23625433
2.

Cyclosporine markedly raises the plasma concentrations of repaglinide.

Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2005 Oct;78(4):388-99.

PMID:
16198658
3.

Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.

Kalliokoski A, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M.

Clin Pharmacol Ther. 2008 Oct;84(4):488-96.

PMID:
19238654
4.

Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.

Kalliokoski A, Backman JT, Neuvonen PJ, Niemi M.

Pharmacogenet Genomics. 2008 Nov;18(11):937-42. doi: 10.1097/FPC.0b013e32830d733e.

PMID:
18854776
5.

Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.

He J, Qiu Z, Li N, Yu Y, Lu Y, Han D, Li T, Zhao D, Sun W, Fang F, Zheng J, Fan H, Chen X.

Eur J Clin Pharmacol. 2011 Jul;67(7):701-7. doi: 10.1007/s00228-011-0994-7. Epub 2011 Feb 17.

PMID:
21327909
6.

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.

Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M.

J Clin Pharmacol. 2008 Mar;48(3):311-21. doi: 10.1177/0091270007311569. Epub 2008 Jan 10.

PMID:
18187595
7.
8.

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.

Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M.

Br J Clin Pharmacol. 2008 Dec;66(6):818-25. doi: 10.1111/j.1365-2125.2008.03287.x. Epub 2008 Sep 23.

9.

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.

Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivistö KT, Neuvonen PJ.

Clin Pharmacol Ther. 2005 Jun;77(6):468-78.

PMID:
15961978
10.

The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide.

Fan L, Zhou G, Guo D, Liu YL, Chen WQ, Liu ZQ, Tan ZR, Sheng D, Zhou HH, Zhang W.

Clin Pharmacokinet. 2011 Sep;50(9):605-11. doi: 10.2165/11587310-000000000-00000.

PMID:
21827215
11.

Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin.

Hu M, Mak VW, Yin OQ, Chu TT, Tomlinson B.

Drug Metab Pharmacokinet. 2013;28(2):104-8. Epub 2012 Jul 31.

12.

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.

Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, Neuvonen PJ.

Drug Metab Dispos. 2009 Dec;37(12):2359-66. doi: 10.1124/dmd.109.029728. Epub 2009 Sep 22.

13.

The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.

Xiang Q, Cui YM, Zhao X, Yan L, Zhou Y.

Pharmacology. 2012;89(1-2):105-10. doi: 10.1159/000336345. Epub 2012 Mar 6.

PMID:
22398664
14.

Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.

Tomalik-Scharte D, Fuhr U, Hellmich M, Frank D, Doroshyenko O, Jetter A, Stingl JC.

Drug Metab Dispos. 2011 May;39(5):927-32. doi: 10.1124/dmd.110.036921. Epub 2011 Jan 26.

15.

Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.

Kajosaari LI, Niemi M, Backman JT, Neuvonen PJ.

Clin Pharmacol Ther. 2006 Mar;79(3):231-42. Epub 2006 Feb 7.

PMID:
16513447
16.

Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.

Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, Jang IJ.

Clin Pharmacol Ther. 2005 Oct;78(4):342-50.

PMID:
16198653
17.

Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.

Gertz M, Tsamandouras N, Säll C, Houston JB, Galetin A.

Pharm Res. 2014 Sep;31(9):2367-82. doi: 10.1007/s11095-014-1333-3. Epub 2014 Mar 13.

PMID:
24623479
18.

OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers.

Wen J, Xiong Y.

J Clin Pharm Ther. 2010 Feb;35(1):99-104. doi: 10.1111/j.1365-2710.2009.01071.x.

PMID:
20175818
19.

The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.

Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH, Shin JG.

Pharmacogenet Genomics. 2008 May;18(5):424-33. doi: 10.1097/FPC.0b013e3282fb02a3.

PMID:
18408565
20.

SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.

Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y.

Clin Pharmacol Ther. 2007 Nov;82(5):541-7. Epub 2007 Apr 25.

PMID:
17460607

Supplemental Content

Support Center